Oscient’s Factive To Get Advisory Committee Review For Acute Bacterial Sinusitis
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Anti-Infective Drugs Advisory Committee will review Oscient’s sNDA for the antibiotic Sept. 12.
You may also be interested in...
Schering’s Antibiotic Garenoxacin Gets Advisory Committee Date
FDA's Anti-Infective Drugs Advisory Committee will discuss Schering-Plough's antibiotic garenoxacin on Sept. 11, according to a Federal Register pre-publication announcement July 24
Schering’s Antibiotic Garenoxacin Gets Advisory Committee Date
FDA's Anti-Infective Drugs Advisory Committee will discuss Schering-Plough's antibiotic garenoxacin on Sept. 11, according to a Federal Register pre-publication announcement July 24
Oscient Will Pursue Factive Sinusitis Claim Despite FDA Refusal To File
FDA accepted Oscient’s sNDA for gemifloxacin for the five-day treatment of mild to moderate community-acquired pneumonia.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: